1.
Convalescent plasma in the treatment of severe covid-19: A systematic review and meta-analysis
Zhang X, Xi L, Pang F, Du Y, Yuan Q, Shi M, Liu J, Ma H, Li B
Iranian Journal of Public Health. 2020;49(11):2022-2031
Abstract
Background: COVID-19 is a public health emergency of international concern Its incidence rates and mortality are very high;however, so far, an effective drug treatment remains unknown Based on the role of convalescent plasma therapy in previously identified viral pneumonias, patients with severe COVID-19 have been given this therapy This systematic review and meta-analysis aimed to summarize the clinical evidence regarding the efficacy and safety of convalescent plasma therapy in the treatment of severe COVID-19 Methods: PubMed, Embase, Ovid, China Knowledge Network, China Biomedical, VIP Chinese Sci-tech Journal, Wanfang Database, and the International Clinical Trials Registry Platform were searched up to 21 June 2020, to identify clinical studies and registered trials on the use of convalescent plasma in the treatment of critically ill patients with COVID-19 Stata 13 0 was used to perform Meta-analysis All records were screened as per the protocol eligibility criteria Results: Nineteen clinical reports regarding convalescent plasma in the treatment of severe COVID-19 were included Through systematic analysis, convalescent plasma was found to yield some efficacy on severe COVID-19 and had almost no obvious adverse reactions Conclusion: Convalescent plasma therapy seems to yield some efficacy among patients with severe COVID-19 and almost no obvious adverse reactions were found However, at present, the clinical evidence is insufficient, and there is an urgent need for support from high-quality clinical trial data © 2020, Iranian Journal of Public Health All rights reserved
2.
Outcomes of platelet-rich plasma for plantar fasciopathy: a best-evidence synthesis
Yu T, Xia J, Li B, Zhou H, Yang Y, Yu G
Journal of orthopaedic surgery and research. 2020;15(1):432
Abstract
BACKGROUND Plantar fasciopathy (PF) is a very common disease, affecting about 1/10 people in their lifetime. Platelet-rich plasma (PRP) had been demonstrated to be useful in achieving helpful effects for plantar fasciopathy. The purpose of this study was to compare the pain and functional outcomes between PRP and corticosteroid (CS) or placebo for plantar fasciopathy through meta-analysis and provide the best evidence. METHODS Literature was searched systematically to explore related studies that were published in Cochrane Library, PubMed, Embase, Medline, SpringerLink, OVID, and ClinicalTrials.gov . Articles regarding comparative research about the outcomes of PRP therapy and CS or placebo injection were selected. Data of pain and functional outcomes was extracted and imported into Reviewer Manager 5.3 to analyze. RESULTS Thirteen RCTs were included and analyzed. Analysis results showed significant superiority of PRP in outcome scores when compared with CS (VAS: MD = - 0.85, P < 0.0001, I(2) = 85%; AOFAS MD = 10.05, P < 0.0001, I(2) = 85%), whereas there is no statistical difference in well-designed double-blind trials (VAS: MD = 0.15, P = 0.72, I(2) = 1%; AOFAS MD = 2.71, P = 0.17, I(2) = 0%). In the comparison of the PRP and the placebo, the pooled mean difference was - 3.76 (P < 0.0001, 95% CI = - 4.34 to - 3.18). CONCLUSIONS No superiority of PRP had been found in well-designed double-blind studies, whereas it is implied that the outcomes of PRP are better than placebo based on available evidence.
3.
The effect of preprocessing stored red blood cells on neonates undergoing corrective cardiac surgery
Liu J, Ji B, Feng Z, Zhao J, Li C, Li B, Long C
ASAIO Journal (American Society for Artificial Internal Organs : 1992). 2007;53((6):):680-3.
Abstract
This study compared the effect of unprocessed and processed packed red blood cells (PRBCs) with the continuous autotransfusion system (CATS) during neonate heart surgery. Sixteen neonatal patients undergoing cardiac surgery were randomly divided into two groups: unprocessed PRBC (C group, n = 8); processed PRBC (P group, n = 8). The CATS was employed perioperatively. Series laboratory and clinical parameters, including levels of hematocrit, blood potassium, blood glucose, blood lactate, acid-base, and total priming volume of PRBC, were used to compare the effect between the two groups. Before CPB, the hematocrit of processed PRBCs in P group was significantly higher than those in C group (p < 0. 01), and the concentrations of potassium, blood glucose, and lactate of processed PRBCs in P group were significantly lower than those in C group (p < 0. 01). At the beginning and the end of CPB, the hematocrit levels in P group were all higher than those in C group (p < 0. 05); lactate levels in P group were significantly lower than those in C group at the beginning of CPB (p < 0. 01), and lower than that of C group at the end of CPB (p < 0. 05). The total priming of PRBCs in P group was significantly less than that in C group (p < 0. 01). Perioperative processing with CATS provided a high-quality RBC concentration, decreased the total priming of PRBCs, providing increased high-quality blood salvage during neonatal CPB procedure.